CMS has finalized a decision to cover HPV testing once every five years for women 30 to 65 years old.” (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, July 14, 2015 /EINPresswire.com/ --

“Infected with the human papillomavirus (HPV)? The Center for the Biology of Chronic Disease (CBCD), recommends taking Gene-Eden-VIR or Novirin against the latent form of the virus.” - Greg Bennett, CBCD

Women with no symptoms of a human papillomavirus (HPV) infection, and who wish to be screened for the virus, will now be able to take advantage of insurance coverage provided by Medicare and Medicaid. The testing is to be provided “once every five years - in conjunction with a Pap smear test - as an additional preventive service.” (1) Dr. Robert Wergin said of that CMS decision that “This decision is consistent with the best medical evidence, and provides women and their physicians more options for cervical cancer screening.” (1) Dr. Wergin is the president of the American Academy of Family Physicians (AAFP). He continued, saying that “The combination of cytology with HPV testing allows women the choice to have less frequent screening without increasing their risk of developing cervical cancer.” (1) According to the report by AAFP, the organization played a significant role in the CMS decision. “In his letter to CMS Chief Medical Officer Patrick Conway, M.D., (then) AAFP Board Chair Jeff Cain, M.D., of Denver, wrote that approving coverage for screening with a combination of Pap smear and HPV testing every five years would make Medicare coverage 'consistent with the clinical recommendations of the USPSTF and AAFP.'” (1)

The Center for the Biology of Chronic Disease (CBCD) endorses this move by the CMS. Wider access to early HPV detection is important for women who may already be infected with an oncogenic (cancer causing) strain of the HPV virus, but who show no symptoms. The CBCD recommends that women who suspect that they are infected with HPV take Gene-Eden-VIR or Novirin. The formula of these natural antiviral products was shown to reduce symptoms associated with HPV infection in two separate post-marketing clinical studies that followed FDA guidelines.

Click to learn more about HPV symptoms.

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the HPV…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (2) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (2)

Both products can be ordered online at the products' respective websites, here:

http://www.gene-eden-vir.com

and

http://www.novirin.com

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

The CMS decision memo noted that “the evidence is sufficient to add Human Papillomavirus (HPV) testing once every five years as an additional preventive service benefit under the Medicare program for asymptomatic beneficiaries aged 30 to 65 years in conjunction with the Pap smear test. CMS will cover screening for cervical cancer with the appropriate U.S. Food and Drug Administration (FDA) approved/cleared laboratory tests, used consistent with FDA approved labeling and in compliance with the Clinical Laboratory Improvement Act (CLIA) regulations.” (3)

This new coverage will enable many more women to take advantage of HPV screening services than in the past. This is important since the CDC notes that “HPV may … be passed on during oral sex and genital-to-genital contact. HPV can be passed on between straight and same-sex partners-even when the infected partner has no signs or symptoms.” (4).

Are there treatments available against the HPV?

“There are no drugs approved against the HPV. Current treatments include procedures, such as cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus. The procedures do not target cells with the latent virus. Since they do not remove the latent virus, these procedures only produce a temporary remission.” (2) In contrast, Novirin and Gene-Eden-VIR were designed to target the latent HPV.

“We recommend that women of all ages practice safe sex, and take Gene-Eden-VIR or Novirin to help the immune system target the latent HPV.” - Greg Bennett, CBCD

All orders of Gene-Eden-VIR and Novirin are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

Reference:

(1) AAFP.org - "CMS to Cover HPV Testing With Pap Smear to Screen for Cervical Cancer" Published July 11, 2015.

(2) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U-s9ouOSz90
(3) CMS.gov - "Proposed Decision Memo for Screening for Cervical Cancer with Human Papillomavirus (HPV) Testing (CAG-00442N)" Issued April 16, 2015

(4) CDC - Human Papillomavirus (HPV) - What is HPV? Last updated on February 5, 2013.
http://www.cdc.gov/hpv/whatishpv.html

Greg Bennett
CBCD
585-250-9999
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.